(S)-2-((3,4-dimethylphenoxy)methyl)oxirane | 256372-75-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (S)-2-((3,4-dimethylphenoxy)methyl)oxirane
• 英文别名: (S)-2-[(3,4-dimethylphenoxy)methyl]oxirane；(S)-glycidyl 3,4-dimethylphenyl ether；(2S)-2-[(3,4-dimethylphenoxy)methyl]oxirane
• CAS: 256372-75-5
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.231
• InChiKey: ZABVHXJGMITPLQ-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-2-((3,4-dimethylphenoxy)methyl)oxirane 在 吡啶 、 盐酸 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 4.0h， 生成 (S)-1-(3,4-dimethylphenoxy)-3-(morpholin-4-yl)propan-2-ol hydrochloride
  参考文献：
  名称：

  Nonracemic Dimethylphenyl Glycerol Ethers in the Synthesis of Physiologically Active Aminopropanols

  摘要：

  Six regioisomeric nonracemic dimethylphenyl glycerol ethers were synthesized by asymmetric dihydroxylation of the corresponding allyl dimethylphenyl ethers. The enantioselectivity of the reaction with o-methyl derivatives was lower (down to 34% ee) than with m-methylphenyl ethers (up to 86% ee). Enantiomeric 3-(3,4-dimethylphenoxy)propane-1,2-diols were used to obtain enantiomerically pure physiologically active amino alcohols and their derivatives.

  DOI：

  10.1134/s1070428019060149
• 作为产物：
  描述：

  3,4-二甲基苯酚 在 potassium carbonate 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 水 、 丙酮 、 叔丁醇 为溶剂， 反应 56.0h， 生成 (S)-2-((3,4-dimethylphenoxy)methyl)oxirane
  参考文献：
  名称：

  Nonracemic Dimethylphenyl Glycerol Ethers in the Synthesis of Physiologically Active Aminopropanols

  摘要：

  Six regioisomeric nonracemic dimethylphenyl glycerol ethers were synthesized by asymmetric dihydroxylation of the corresponding allyl dimethylphenyl ethers. The enantioselectivity of the reaction with o-methyl derivatives was lower (down to 34% ee) than with m-methylphenyl ethers (up to 86% ee). Enantiomeric 3-(3,4-dimethylphenoxy)propane-1,2-diols were used to obtain enantiomerically pure physiologically active amino alcohols and their derivatives.

  DOI：

  10.1134/s1070428019060149

文献信息

• Use of 5HT-1F receptor antagonists for treating anxiety disorders
  申请人：ELI LILLY AND COMPANY

  公开号：EP0976747A3

  公开（公告）日：2000-09-13

  The present invention provides a method for the treatment of prevention of anxiety disorders which comprises administering to a mammal in need of such treatment a serotonin 5-HT1F receptor antagonist.

  本发明提供了一种治疗预防焦虑症的方法，包括向需要此类治疗的哺乳动物施用一种5-HT1F受体拮抗剂。
• 5-HT1F antagonists
  申请人：Eli Lilly and Company

  公开号：US06242450B1

  公开（公告）日：2001-06-05

  This invention provides 5-HT1f antagonists of Formula I: where AR1, AR2, R, and R′ are as defined in the specification.

  这项发明提供了化学式I中的5-HT1f拮抗剂：其中AR1、AR2、R和R'如规范中所定义。
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：ISIS INNOVATION

  公开号：WO2015004485A1

  公开（公告）日：2015-01-15

  The present invention relates to therapeutic compounds useful for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia). The compounds have the structural formula I shown below: wherein Q, X, p, R1, q, R3 and R4 are as defined herein. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, the use of these compositions for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia), and to processes for the preparation of the pharmaceutical compositions defined herein.

  本发明涉及治疗化合物，用于治疗神经退行性疾病、神经肌肉疾病和/或三联重复疾病（如弗里德雷希共济失调）。这些化合物具有下面显示的结构式I：其中Q、X、p、R1、q、R3和R4的定义如本文所述。本发明还涉及包含上述定义的化合物的药物组合物，以及利用这些组合物治疗神经退行性疾病、神经肌肉疾病和/或三联重复疾病（如弗里德雷希共济失调）的用途，以及用于制备上述药物组合物的过程。
• [EN] TREATMENT OF ANXIETY DISORDERS<br/>[FR] TRAITEMENT DES TROUBLES ANXIEUX
  申请人：LILLY CO ELI

  公开号：WO2000006082A2

  公开（公告）日：2000-02-10

  The present invention provides a method for the treatment or prevention of anxiety disorders which comprises administering to a mammal in need of such treatment a serotonin 5-HT1F receptor antagonist.
• [EN] 5-HT1F ANTAGONISTS<br/>[FR] ANTAGONISTES DE 5-HT1F
  申请人：LILLY CO ELI

  公开号：WO2000006166A1

  公开（公告）日：2000-02-10

  This invention provides 5-HT1F antagonists of Formula (I) where AR1, AR2, R, and R' are as defined in the specification.